Allumiqs and Prolytix have joined forces to provide integrated solutions aimed at enhancing customer success in the realm of drug development pipelines. By combining their expertise in bioanalytical solutions and large-molecule drug product lifecycle management, the partners aim to streamline processes and optimize efficiency from R&D phases to lot release.
Allumiqs, known for its multiomics and LC-MS/MS solutions, offers biological insights and therapeutic characterization in the early stages of R&D. This valuable information sets the stage for seamless collaboration with Prolytix for subsequent targeted method development and testing. By working together, the two companies offer customers connected solutions and a team of experts to reduce the complexities associated with transferring critical R&D work between vendors.
Kent MacLean, CEO of Allumiqs, expressed excitement about the partnership, highlighting the shared commitment to customer success as a driving force behind the collaboration with Prolytix. Together, the companies aim to simplify the engagement process for customers, offering innovative solutions at every stage of drug discovery.
David Halverson, President, and CEO of Prolytix, echoed MacLean’s sentiments, emphasizing how the partnership expands their portfolio to better support biopharma research and development initiatives. By leveraging their combined expertise, Prolytix and Allumiqs provide a robust scientific platform to optimize biopharma research efforts.
Allumiqs and Prolytix are dedicated to empowering customers with comprehensive solutions that reduce time-to-value, optimize R&D investments, and accelerate advancements in the drug development pipeline. Through this strategic partnership, they aim to make the journey from R&D to lot release smoother and more efficient for biotech and biopharma companies.
For more information about Allumiqs and Prolytix, visit their respective websites at allumiqs.com and goprolytix.com. Stay tuned for more groundbreaking collaborations and innovative solutions from these two industry leaders in the field of drug development and bioanalytical services.
Media Contact:
Allumiqs – Andrea Young
Prolytix – John Moriarty
SOURCE: Prolytix
Image: Prolytix Logo (link included)
Source link
